MedTrace Logo

Effects of Denosumab Therapy for Japanese

NCT02491515 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-11-25

No results posted yet for this study

Summary

In this study, the investigators would like to analyze the bone mineral density (BMD) , bone turnover makers, and fracture prevention effects of denosumab in Japanese patients under clinical practice. The participants are treated in the investigators hospital, who are under severe osteoporotic condition.

The main objective of this study is to investigate effects of denosumab. The researchers also investigate the effects of Effects of previous osteoporotic therapy to denosumab treatment. In this study, the investigators analyse the determinants of subsequent BMD increase and fracture preventing effect by teriparatide.

Conditions

Interventions

DRUG

Denosumab

every 6 month injection

Sponsors & Collaborators

  • Tomidahama Hospital

    lead OTHER

Principal Investigators

  • Rui Niimi, MD · Tomidahama Hospital

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2017-06-30
Completion
2020-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02491515 on ClinicalTrials.gov